Document:

Fourth Agreement to Amend the Floating Rate Note Support Agreement

 EXHIBIT 10.2 
 EXECUTION 
 FOURTH AGREEMENT TO AMEND THE FLOATING RATE NOTE SUPPORT
AGREEMENT 
 THIS FOURTH AMENDMENT is made as of this 27th day of January 2011. 

WHEREAS, (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule
A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto, each Consenting Noteholder being a holder of and/or investment advisor or
manager with investment discretion over Floating Rate Notes, executed a Floating Rate Note Support Agreement dated as of October 29, 2010 concerning the principal aspects of an Exchange of Floating Rate Notes (as amended by the First Amendment,
the Second Amendment and the Third Amendment, the “Support Agreement”); 
 AND WHEREAS, pursuant to
Section 15(n) of the Support Agreement, the Support Agreement may be modified, amended or supplemented as to any matter by an instrument in writing signed by the Companies and Consenting Noteholders that represent not less than a majority of
the outstanding Floating Rate Notes; 
 AND WHEREAS, the Consenting Noteholders representing not less than a majority of
the aggregate principal amount of outstanding Floating Rate Notes executed an Agreement to Amend the Floating Rate Note Support Agreement dated as of November 29, 2010 (the “First Amendment”); 

AND WHEREAS, the Consenting Noteholders representing not less than a majority of the aggregate principal amount of outstanding
Floating Rate Notes executed a Second Agreement to Amend the Floating Rate Note Support Agreement dated as of December 15, 2010 (the “Second Amendment”); 
 AND WHEREAS, the Consenting Noteholders representing not less than a majority of the aggregate principal amount of outstanding Floating Rate Notes executed a Third Agreement to Amend the Floating
Rate Note Support Agreement dated as of January 11, 2011 (the “Third Amendment”); 
 AND
WHEREAS, the Consenting Noteholders party to this fourth amendment (the “Fourth Amendment”) wish to further amend the Support Agreement in the manner set out in this Fourth Amendment; 

AND WHEREAS, the Consenting Noteholders party to this Fourth Amendment collectively hold and/or exercise investment discretion
over not less than a majority of the Floating Rate Notes; 
 NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Companies and the Consenting Noteholders party hereto hereby agree as follows: 

	1.	Capitalized Terms 

Capitalized Terms that are used but not otherwise defined herein shall have the meanings ascribed thereto in the Support Agreement.

  

	2.	Consenting Noteholders Party to this Fourth Amendment 

 Each Consenting Noteholder party to this Fourth Amendment hereby represents and warrants, severally and not jointly, to each of the other parties to this Fourth Amendment (and acknowledges that each of
the other parties to this Fourth Amendment is relying upon such representations and warranties) that as of the date hereof: (a) it either (i) is the sole legal and beneficial owner of the principal amount of Floating Rate Notes disclosed
to Goodmans LLP (“Goodmans”) as of such date, or (ii) has the investment and voting discretion with respect to the principal amount of Floating Rate Notes disclosed to Goodmans as of such date; (b) it has the power and
authority to bind the beneficial owner(s) of such Floating Rate Notes to the terms of this Fourth Amendment; and (c) it has authorized and instructed Goodmans to advise Angiotech, in writing, of the aggregate amount of Floating Rate Notes held
by the Consenting Noteholders that are party to this Fourth Amendment. 
  

	3.	Amendments to the Support Agreement 

 The Support Agreement is hereby amended by deleting the reference to “January 28, 2011” in Section 5(d) of the Support Agreement and replacing it with “February 7, 2011”.

  

	4.	Support Agreement to apply in full force and effect 

 Except as expressly modified by the terms of this Fourth Amendment, the terms and conditions of the Support Agreement shall continue to apply in full force and effect, unamended. 

 

	5.	Miscellaneous 

  

	 	(a)	This Fourth Amendment may be modified, amended or supplemented as to any matter by an instrument in writing signed by the Companies and Consenting Noteholders that
represent not less than a majority of the Floating Rate Notes. 

  

	 	(b)	This Fourth Amendment shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein,
without regard to principles of conflicts of law. Each of the parties to this Fourth Amendment submits to the jurisdiction of the courts of the Province of Ontario in any action or proceeding arising out of or relating to this Fourth Amendment.

  

	 	(c)	This Fourth Amendment may be signed in counterparts, each of which, when taken together, shall be deemed an original. Execution of this Fourth Amendment is effective if
a signature is delivered by facsimile transmission or electronic (e.g., pdf) transmission. 

 [The
remainder of this page is intentionally left blank] 

  
 - 2 -

 This Fourth Amendment has been agreed and accepted on the date first written above.

  

			
	ANGIOTECH PHARMACEUTICALS, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: Chief Financial Officer
	
	AFMEDICA, INC.;
	AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.;
	ANGIOTECH AMERICA, INC.;
	ANGIOTECH BIOCOATINGS CORP.;
	ANGIOTECH DELAWARE, INC.;
	ANGIOTECH FLORIDA HOLDINGS, INC.;
	ANGIOTECH PHARMACEUTICALS (US), INC.;
	B.G. SULZLE, INC.;
	MANAN MEDICAL PRODUCTS, INC.;
	MEDICAL DEVICE TECHNOLOGIES, INC.;
	NEUCOLL, INC.;
	QUILL MEDICAL, INC.;
	SURGICAL SPECIALTIES CORPORATION;
	SURGICAL SPECIALTIES PUERTO RICO, INC.; and
	SURGICAL SPECIALTIES UK HOLDINGS LIMITED
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

 
			
	ANGIOTECH INTERNATIONAL HOLDINGS CORP.; and
	
	0741693 B.C. LTD.
		
	By:	 	 /s/ Jay Dent

		 	Name: Jay Dent
		 	Title: PresidentSupplemental Indenture, dated January 27, 2011

 EXHIBIT 10.3 
 EXECUTION COPY 
 SUPPLEMENTAL INDENTURE 

SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of January 27, 2011, among Angiotech
Pharmaceuticals, Inc., a corporation organized under the Business Corporation Act of the Province of British Columbia (the “Company”), the Guarantors under the Indenture (as defined and referred to below) and U.S. Bank National
Association, as successor to Deutsche Bank National Trust Company, successor to Wells Fargo Bank, N.A., as trustee (the “Trustee”) under the Indenture. All capitalized terms used but not otherwise defined herein shall have the
meaning assigned thereto in the Indenture. 
 W I T N E S S E T H : 

WHEREAS, the Company and the Guarantors have heretofore executed and delivered to the Trustee an Indenture, dated as of March 23,
2006 (as amended, supplemented or otherwise modified from time to time, the “Indenture”), providing for the issuance of the Company’s 7.75% Senior Subordinated Notes Due 2014 (the “Notes”); 

WHEREAS, Section 9.02 of the Indenture provides that under certain circumstances the Company and the Trustee, with the consent of
the holders of at least a majority in aggregate principal amount of the outstanding Notes, may amend or supplement the Indenture; 
 WHEREAS, on October 29, 2010, the Company and the Guarantors entered into a supplemental indenture in order to extend the grace period for payment of interest due on the Notes from 30 days to 60 days
prior to the occurrence of an Event of Default; 
 WHEREAS, on November 29, 2010, the Company and the Guarantors entered
into a supplemental indenture in order to further extend the grace period for payment of interest due on the Notes from 60 days to 90 days prior to the occurrence of an Event of Default; 

WHEREAS, on December 21, 2010, the Company and the Guarantors entered into a supplemental indenture in order to further extend the
grace period for payment of interest due on the Notes from 90 days to 120 days prior to the occurrence of an Event of Default; 

WHEREAS, the Board of Directors of the Company has determined that it is in the Company’s best interest to enter into, and has
authorized the execution of, this Supplemental Indenture in order to further extend the grace period for payment of interest due on the Notes from 120 days to 211 days prior to the occurrence of an Event of Default (the
“Amendment”); 
 WHEREAS, the holders of at least a majority in aggregate principal amount of the outstanding
Notes have consented to the Amendment and the Company has filed with the Trustee evidence of such consent satisfactory to the Trustee; and 
 WHEREAS, pursuant to Section 9.02 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture. 

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby
acknowledged, the parties mutually covenant and agree for the equal and ratable benefit of the Holders as follows: 
 1.
Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force
and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and every holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby. 

 2. Amendment to Indenture. Section 6.01(1) of the Indenture is hereby amended
and restated as follows: 
 “default for 211 days in the payment when due of interest on, or Additional Interest, if any,
with respect to, the Notes, whether or not prohibited by the subordination provisions of this Indenture;” 
 3. Opinion
of Counsel. Concurrently with the execution and delivery of this Supplemental Indenture, the Company shall deliver to the Trustee an Officers’ Certificate and an Opinion of Counsel in accordance with the terms set forth in Sections 7.02,
9.02, 13.04 and 13.05 of the Indenture. 
 4. Successors. All agreements of the Company and the Guarantors in this
Supplemental Indenture shall bind their respective successors. All agreements of the Trustee in this Supplemental Indenture shall bind its successors. 
 5. Governing Law. THE LAW OF THE STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE THIS SUPPLEMENTAL INDENTURE. The parties to this Supplemental Indenture each hereby irrevocably submits to
the non-exclusive jurisdiction of any New York State or federal court sitting in the Borough of Manhattan in The City of New York in any action or proceeding arising out of or relating to the Notes or this Supplemental Indenture, and all such
parties hereby irrevocably agree that all claims in respect of such action or proceeding may be heard and determined in such New York State or federal court and hereby irrevocably waive, to the fullest extent that they may legally do so, the defense
of an inconvenient forum to the maintenance of such action or proceeding. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING ARISING
OUT OF OR RELATING TO THIS SUPPLEMENTAL INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 6.
Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy (including any facsimile) shall be an original, but all of them together represent the same agreement. 

7. Effect of Headings. The Section headings herein are for convenience only and shall not effect the construction thereof.

 8. Trustee. The Trustee makes no representations as to the validity or sufficiency of this Supplemental Indenture. The
recitals and statements herein are deemed to be those of the Company and the Guarantors and not of the Trustee. 
 9.
Severability. In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 10. Trust Indenture Act Controls. If any provision of this Supplemental Indenture limits, qualifies or conflicts with
another provision that is required to be included in this Supplemental Indenture or the Indenture by the Trust Indenture Act of 1939, as amended, as in force at the date that this Supplemental Indenture is executed, the provisions required by said
Act shall control. 
 [Remainder of Page Intentionally Left Blank; Signature Pages Follow] 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first above written. 
  

					
	ANGIOTECH PHARMACEUTICALS, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: Chief Financial Officer

  
 [Signature
Page to Supplemental Indenture] 

 
			
	0741693 B.C. LTD.
		
	By:	 	 /s/ Jay Dent

		 	Name: Jay Dent
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	AFMEDICA, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	ANGIOTECH AMERICA, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	ANGIOTECH BIOCOATINGS CORP.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	ANGIOTECH DELAWARE, INC. (F/K/A AMERICAN MEDICAL INSTRUMENTS, INC.)
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	ANGIOTECH FLORIDA HOLDINGS, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	ANGIOTECH INTERNATIONAL HOLDINGS, CORP.
		
	By:	 	 /s/ Jay Dent

		 	Name: Jay Dent
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	ANGIOTECH PHARMACEUTICALS (US), INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	B.G. SULZLE, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	MANAN MEDICAL PRODUCTS, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	MEDICAL DEVICE TECHNOLOGIES, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	NEUCOLL, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	QUILL MEDICAL, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	SURGICAL SPECIALTIES CORPORATION
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	SURGICAL SPECIALTIES PUERTO RICO, INC.
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	SURGICAL SPECIALTIES UK HOLDINGS LIMITED
		
	By:	 	 /s/ K. Thomas Bailey

		 	Name: K. Thomas Bailey
		 	Title: President

  
 [Signature
Page to Supplemental Indenture] 

 
			
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
		
	By:	 	 /s/ Timothy Sandell

		 	Name: Timothy Sandell
		 	Title: Vice President

  
 [Signature
Page to Supplemental Indenture]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]